Prelude Therapeutics Incorporated (PRLD) Tops Q2 EPS by 9c
Tweet
Share
E-mailGet Alerts PRLD Hot Sheet
Join SI Premium – FREE
Prelude Therapeutics Incorporated (NASDAQ: PRLD) reported Q2 EPS of ($0.14), $0.09 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $5.71 million.
For earnings history and earnings-related data on Prelude Therapeutics Incorporated (PRLD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
- Acrivon Therapeutics, Inc. (ACRV) Tops Q2 EPS by 21c
- Epsilon Energy Ltd. (EPSN) Reports Q2 EPS of $0.23
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
